Avalo Therapeutics, Inc. (AVTX), the clinical-stage biotechnology company announced the appointment of Jennifer Riley as chief strategy officer with effect from January 1. Shares are down 1.75 percent in the pre-market.
Riley will be responsible for managing corporate strategy and planning the commercial and product pipeline, aiming to boost growth and innovation in the company. She has over 20 years of experience in the biotechnology and pharmaceutical industries.
Thursday, AVTX had closed 4.74% less at $7.43 on the Nasdaq. In the pre-market trading, AVTX is 1.75% high at $7.30.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.